Zusammenfassung:
Schizophrene Psychosen sind rezidivierende Erkrankungen. Hauptziel neuroleptischer
Langzeitbehandlung ist die Rezidivprophylaxe, deren Wirksamkeit empirisch gut belegt
ist. Verschiedene Behandlungsstrategien einschließlich der Verfügbarkeit neuer Neuroleptika
mit günstigerem Wirkungs-/Nebenwirkungs-Profil erlauben eine individuell angepasste
Langzeitbehandlung. Zumeist von den wissenschaftlich-medizinischen Fachgesellschaften
entwickelte Praxisleitlinien geben entsprechende Behandlungsempfehlungen vor.
Strategies of Long-Term Medication in Schizophrenia:
Schizophrenia is a relapsing disorder. The main goal of neuroleptic long-term treatment
is relapse prevention, which is empirically well proven. Availability of different
kinds of treatment strategies including new antipsychotic drugs with improved risk/benefit
profile allow long-term treatment to be individually tailored. Treatment guidelines
developed mainly by the scientific medical societies can help the practitioner in
making the right decisions.
Literatur
- 1
Altamura A C, Barnas C, Bitter I, Fleischhacker W, Gaebel W, Hirsch S, Kissling W,
Küfferle B, Möller H J, Naber D, Pickar D, Pullen I, Tollefson G D.
Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.
International Journal of Psychiatry in Clinical Practice.
1997;
1
25-30
- 2
Andrews S, Vaughan K, Harvey R, Andrews GT.
A survey of practising psychiatrists' views on the treatment of schizophenia.
Br J Psychiatry.
1986;
149
357-364
- 3 American Psychiatric Association .Practice Guideline for the Treatment of Patients
with Schizophrenia. Washington: APA 1997
- 4
Barnes T RE, Milavic G, Curson D A, Platt S D.
Use of the social behavior assessment schedule (SBAS) in a trial of maintenance antipsychotic
therapy in schizophrenic outpatients: Pimozide vs fluphenazine.
Soc Psychiat.
1983;
18
193-199
- 5
Bassett A, Addington D.
Canadian clinical practice guidelines for the treatment of schizophrenia.
The Canadian Journal of Psychiatry.
1998;
43 (suppl. 2)
25-40
- 6
Bleuler M, Huber G, Gross G, Schüttler R.
Der langfristige Verlauf schizophrener Psychosen.
Nervenarzt.
1976;
47
477-481
- 7 Brown G W, Bone M, Dalison B, Wing J K. Schizophrenia and social care. Oxford: University
Press 1966
- 8
Chiles J A, Sterchi D, Hyde T, Herz M I.
Intermittent medication for schizophrenic outpatients: Who is eligible?.
Schizophrenia Bulletin.
1989;
15
117-121
- 9
Christison G W, Kirch D G, Wyatt R J.
When symptoms persist: Choosing among alternative somatic treatments for schizophrenia.
Schizophrenia Bulletin.
1991;
17
217-245
- 10
Cheung H K.
Schizophrenics full remitted on neuroleptics for 3 to 5 years - to stop or continue
drugs?.
Brit J Psychat.
1981;
138
490-494
- 11
Davis J M.
Maintenance therapy and the natural course of schizophrenia.
J Clin Psychiatry.
1985;
11
18-21
- 12
Davis J M, Schaffer C B, Killian G A, Kinard C, Chan C.
Important issues in the drug treatment of schizophrenia.
Schizophrenia Bulletin.
1980;
6
70-87
- 13 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN)
.Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1. Behandlungsleitlinie
Schizophrenie. Redaktion: Gaebel W, Fallkai P Darmstadt: Steinkopff 1998
- 14 Dietmaier O. Interaktionen. In: Riederer P, Laux G, Pöldinger W (Hrsg.). Neuro-Psychopharmaka.
Ein Therapie-Handbuch. Band 4: Neuroleptika Wien: Springer 1988: 177-196
- 15
Frances A, Docherty J P, Kahn D A.
The expert consensus guidelines series. Treatment of schizophrenia. Schizophrenia
Bulletin.
J Clin Psychiatry.
1996;
57 (suppl. 12B)
1-58
- 16
Gaebel W.
Tardive Dyskinesien unter Neuroleptika-Behandlung.
Deutsches Ärzteblatt.
1993;
90
1041-1046
- 17
Gaebel W.
Intermittent medication - an alternative?.
Acta Psychiatrica Scand.
1994;
89 (suppl. 382)
33-38
- 18 Gaebel W. Internationale Leitlinien der Schizophreniebehandlung. In: Möller HJ,
Müller N (Hrsg.). Stellenwert atypischer Neuroleptika Heidelberg: Springer 1999a
- 19 Gaebel W. Long-term treatment in schizophrenia - for whom and how long? Commentary. In:
WPA (Hrsg.). Evidence & Experience in Psychiatry London: Wiley 1999b
- 20 Gaebel W, Awad A G. Prediction of neuroleptic treatment outcome in schizophrenia
- concepts and methods. Wien: Springer 1994
- 21
Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzcker A, Tegeler J.
Early neuroleptic intervention in schizophrenia: Are prodromal symptoms valid predictors
of relapse.
Brit J Psychiatry.
1993;
163 (suppl. 21)
8-12
- 22
Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpcke W, Linden M, Müller P, Müller-Spahn F,
Tegeler J.
Prodromal States in Schizophrenia.
Comprehensive Psychiatry.
2000;
41 (suppl. 1)
76-85
- 23 Gaebel W, Klimke A, Klieser E. Kombination von Clozapin mit anderen Psychopharmaka. In:
Naber D, Müller-Spahn F (Hrsg.). Clozapin. Pharmakologie und Klinik eines atypischen
Neuroleptikums Berlin - Heidelberg - New York: Springer 1994: 43-58
- 24 Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpcke W, Linden M, Müller P, Müller-Spahn F,
Tegeler J. First vs multiple episode schizophrenia: Two-year outcome of intermittent
and maintenance medication strategies. Schizophrenia Research 2001 in press
- 25
Gilbert D A, Altshuler K Z, Rago W V, Shon S P, Crismon M L, Toprac M G, Rush A J.
Texas medication algorithm project: Definitions, rationals and methods to develop
medication algorithms.
J Clin Psychiatry.
1998;
59 (7)
345-351
- 26
Glazer W M, Kane J M.
Depot neuroleptic therapy: An underutilized treatment option?.
J Clin Psychiatry.
1992;
53
426-433
- 27
Glenthøj B, Hemmingsen R, Allerup P, Bolwig T G.
Intermittent versus continuous neuroleptic treatment in a rat model.
Eur J Pharmacolog.
1990;
190
275-286
- 28
Goldberg S C.
Negative and deficit symptoms in schizophrenia do respond to neuroleptics.
Schizophren Bull.
1985;
11
453-456
- 29 Green M F. Schizophrenia from a neurocognitive perspective. Probing the impenetrable
darkness. Boston: Allyn and Bacon 1998
- 30
Grimshaw J M, Russell I T.
Effect of clinical guidelines on medical practice: A systematic review of rigorous
evaluations.
The Lancet.
1993;
342
1317-1322
- 31
Harding C M, Brooks G W, Ashikaga T, Strauss J S, Breier A.
The Vermont longitudinal study of persons with severe mental illness. I. Methodology,
study sample, and overall status 32 years later.
Am J Psychiatry.
1987;
144
728-726
- 32
Hartmann W, Kind J, Meyer J E, Müller P, Steuber H.
Neuroleptic drugs and the prevention of relapse in schizophrenia: A workshop report.
Schizophren Bull.
1980;
6
536-543
- 33
Hegarty J D, Baldessarini R J, Tohen M, Waternaux C, Oepen G.
One hundred years of schizophrenia: A meta-analysis of the outcome literature.
Am J Psychiatry.
1994;
151
1409-1416
- 34
Helmchen H.
Forschungsaufgaben bei psychiatrischer Langzeitmedikation.
Nervenarzt.
1978;
49
534-538
- 35
Herz M I, Melville Ch.
Relapse in schizophrenia.
American Journal of Psychiatry.
1980;
137
801-805
- 36
Hogarty G E, Goldberg S C, Schooler N R, Ulrich R F.
Drug and sociotherapy in the aftercare of schizophrenic patients I. One-year relapse
rates.
Arch Gen Psychiatry.
1973;
28
54-64
- 37
Hogarty G E, Goldberg S C, Schooler N R, Ulrich R F.
Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse
rates.
Arch Gen Psychiatry.
1974;
31
603-608
- 38
Hogarty G E, Ulrich R F, Mussare F, Arishgueta N.
Drug discontinuation among long term, successfully maintained schizophrenic outpatients.
Dis Nerv Syst.
1976;
37
494-500
- 39
Hogarty G E, Schooler N R, Ulrich R, Mussare F, Ferro P, Herron E.
Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse
analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine
hydrochloride.
Arch Gen Psychiatry.
1979;
36
1283-1294
- 40
Jeste D V, Potkin S G, Sinha S, Feder S, Wyatt R.
Tardive dyskinesia - reversible and persistent.
Archives of General Psychiatry.
1979;
36
585-590
- 41
Kane J M, Marder S R.
Psychopharmacologic treatment of schizophrenia.
Schizophrenia Bull.
1993;
19
287-302
- 42
Kane J M, Rifkin A, Quitkin F, Nayak D, Ramoslorenzi J.
Fluphenazine versus placebo in patients with remitted, acute first-episode schizophrenia.
Arch Gen Psychiatry.
1982;
39
70-73
- 43 Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin
- Heidelberg - New York: Springer 1991
- 44 König P, Laux G. Kontrolluntersuchungen. In: Riederer P, Laux G, Pöldinger W (Hrsg.).
Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 4: Neuroleptika Wien: Springer 1998:
177-196
- 45
Lehman A F, Steinwachs D M. , and the Survey Co-Investigators of the PORT Project
.
Translating research into practice: The schizophrenia Patient Outcomes Research Team
(PORT). Treatment Recommendations.
Schizophrenia Bulletin.
1988a;
24 (suppl. 1)
1-10
- 46
Lehman A F, Steinwachs D M. , and the Survey Co-Investigators of the PORT Project
.
Patterns of usual care for schizophrenia: Initial results from the schizophrenia Patient
Outcomes Research TEAM (PORT) Client Survey.
Schizophrenia Bulletin.
1988b;
24
11-20
- 47
Marder S R, Hubbard J W, Van Putten T, Midha K K.
Pharmacokinetics of long-acting injectable neuroleptic drugs: Clinical implications.
Psychopharmacology.
1989;
98
433-439
- 48
Marder S R, Midha K K, Van Putten T, Aravagiri M, Hawes E M, Hubbard J W, McKay G,
Mintz J.
Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: Relationship
to clinical response.
Brit J Psychiatry.
1991;
158
658-665
- 49 May P RA, Goldberg S C. Prediction of schizophrenic patients' response to pharmacotherapy. In:
Lipton MA, Dimascio A, Killam KF (eds.). Psychopharmacology: A generation of progress
New York: Raven Press 1978: 1139-1153
- 50
Maynard A, Bloor K.
Building castles on sands or quicksands?.
British Journal of Psychiatry.
1998;
173 (suppl. 36)
12-18
- 51
McEvoy J P, Scheifler P L, Frances A.
The expert consensus guidelines series. Treatment of Schizophrenia 1999.
J Clin Psychiatry.
1999;
60 (suppl. 36)
1-80
- 52
Möller H J.
Aktuelle Bewertung neuer/atypischer Neuroleptika.
Nervenarzt.
2000a;
71
329-344
- 53
Möller H J.
Neue bzw. atypische Neuroleptika bei schizophrener Negativsymptomatik. Ergebnisse
und methodische Probleme der Evaluation.
Nervenarzt.
2000b;
71
345-353
- 54
National Advisory Mental Health Council .
Health Care Reform for Americans With Severe Mental Illnesses: Report of the National
Advisory Mental Health Council.
American Journal of Psychiatry.
1993;
150
1447-1465
- 55
Osser D N, Zarate C A.
Consultant for the pharmacotherapy of schizophrenia.
Psychiatric Annals.
1999;
29 (5)
252-267
- 56 Peuskens J, De Hert M. Good medical practice. Antipsychotics. Effects and side-effects. Kopenhagen:
Lundbeck 1997
- 57
Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J.
Continuous versus maintenance neuroleptic longterm treatment in schizophrenia - 2-year
results of a German multicenter study.
J Psychiat Res.
1993;
27 (4)
321-399
- 58
Rifkin A, Quitkin F, Rabiner C J, Klein D F.
Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted
schizophrenis. I. Relapse rates after one year.
Arch Gen Psychiatry.
1977;
34
43-47
- 59
Stephens J H.
Long-term prognosis and follow-up in schizophrenia.
Schizophrenia Bull.
1978;
4
25-48
- 60
Tsuang M T, Woolson R F, Fleming J A.
Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared
with psychiatrically symptom-free surgical conditions.
Arch Gen Psychiatry.
1979;
39
1295-1301
- 61
Wyatt R J, Damiani L M, Henter I D.
First episode schizophrenia. Early intervention and medication discontinuation in
the context of course and treatment.
British Journal of Psychiatry.
1998;
172 (suppl. 33)
77-83
- 62
Zarate C A, Daniel D G, Kinon B J, Litman R E, Naber D, Pickar D, Sato M.
Algorithms for the treatment of schizophrenia.
Psychopharmacological Bulletin.
1995;
3
461-464
Prof. Dr. med. Wolfgang Gaebel
Direktor der Klinik und Poliklinik
für Psychiatrie und Psychotherapie
der Heinrich-Heine-Universität Düsseldorf
Rheinische Kliniken Düsseldorf
Bergische Landstraße 2
40629 Düsseldorf
